drugset / Trial / NCT00309049

Ixabepilone Administered as an Enteric Coated Formulation.

NCT00309049

Phase 1/2 Completed 30 enrolled R-Pharm
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.

Timeline

Start
2006-04
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ixabepilone Small molecule 15 mg Oral
Comparator Ixabepilone Small molecule 30 mg Oral
Comparator Ixabepilone Small molecule 40 mg Oral

Indications